Literature DB >> 18369326

Cell vehicle targeting strategies.

J C Roth1, D T Curiel, L Pereboeva.   

Abstract

Use of cells as therapeutic carriers has increased in the past few years and has developed as a distinct concept and delivery method. Cell-based vehicles are particularly attractive for delivery of biotherapeutic agents that are difficult to synthesize, have reduced half-lives, limited tissue penetrance or are rapidly inactivated upon direct in vivo introduction. Initial studies using cell-based approaches served to identify some of the key factors for the success of this type of therapeutic delivery. These factors include the efficiency of cell loading with a therapeutic payload, the means of cell loading and the nature of therapeutics that cells can carry. However, one important aspect of cell-based delivery yet to be fully investigated is the process of actual delivery of the cell payload in vivo. In this regard, the potential ability of cell carriers to provide site-specific or targeted delivery of therapeutics deserves special attention. The present review focuses on a variety of targeting approaches that may be utilized to improve cell-based therapeutic delivery strategies. The different aspects of targeting that can be applied to cell vehicles will be discussed, including physical methods for directing cell distribution, intrinsic cell-mediated homing mechanisms and the feasibility of engineering cells with novel targeting mechanisms. Development of cell targeting strategies will further advance cell vehicle applications, broaden the applicability of this delivery approach and potentiate therapeutic outcomes.

Mesh:

Year:  2008        PMID: 18369326     DOI: 10.1038/gt.2008.38

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  23 in total

1.  Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells.

Authors:  Bonnie Huang; Wuhbet D Abraham; Yiran Zheng; Sandra C Bustamante López; Samantha S Luo; Darrell J Irvine
Journal:  Sci Transl Med       Date:  2015-06-10       Impact factor: 17.956

2.  A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer.

Authors:  Oren Levy; W Nathaniel Brennen; Edward Han; David Marc Rosen; Juliet Musabeyezu; Helia Safaee; Sudhir Ranganath; Jessica Ngai; Martina Heinelt; Yuka Milton; Hao Wang; Sachin H Bhagchandani; Nitin Joshi; Neil Bhowmick; Samuel R Denmeade; John T Isaacs; Jeffrey M Karp
Journal:  Biomaterials       Date:  2016-03-17       Impact factor: 12.479

3.  Targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor.

Authors:  Svetlana Komarova; Justin Roth; Ronald Alvarez; David T Curiel; Larisa Pereboeva
Journal:  J Ovarian Res       Date:  2010-05-25       Impact factor: 4.234

Review 4.  Development of individualized anti-metastasis strategies by engineering nanomedicines.

Authors:  Qianjun He; Shengrong Guo; Zhiyong Qian; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2015-06-09       Impact factor: 54.564

5.  Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs.

Authors:  Miguel G Toscano; Mario Delgado; Weimin Kong; Francisco Martin; Mario Skarica; Doina Ganea
Journal:  Mol Ther       Date:  2010-01-12       Impact factor: 11.454

Review 6.  Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies.

Authors:  Gina Li; Nicolas Bonamici; Mahua Dey; Maciej S Lesniak; Irina V Balyasnikova
Journal:  Expert Opin Drug Deliv       Date:  2017-09-18       Impact factor: 6.648

Review 7.  Monocyte-mediated drug delivery systems for the treatment of cardiovascular diseases.

Authors:  Gil Aizik; Etty Grad; Gershon Golomb
Journal:  Drug Deliv Transl Res       Date:  2018-08       Impact factor: 4.617

8.  A myeloid cell-binding adenovirus efficiently targets gene transfer to the lung and escapes liver tropism.

Authors:  M O Alberti; J S Deshane; D D Chaplin; L Pereboeva; D T Curiel; J C Roth
Journal:  Gene Ther       Date:  2012-11-22       Impact factor: 5.250

9.  Tumor immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds.

Authors:  Marta Compte; Angel M Cuesta; David Sánchez-Martín; Vanesa Alonso-Camino; José Luís Vicario; Laura Sanz; Luís Alvarez-Vallina
Journal:  Stem Cells       Date:  2009-03       Impact factor: 6.277

10.  Evaluation of adenovirus capsid labeling versus transgene expression.

Authors:  Jing Li; Aiman Fatima; Svetlana Komarova; Hideyo Ugai; Priyanka Uprety; Justin C Roth; Minghui Wang; Robert A Oster; David T Curiel; Qiana L Matthews
Journal:  Virol J       Date:  2010-01-26       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.